Issue 1, 2015

Rational design of protein–protein interaction inhibitors

Abstract

Protein–protein interactions are at the heart of most physiopathological processes. As such, they have attracted considerable attention for designing drugs of the future. Although initially considered as high-value but difficult to identify, low molecular weight compounds able to selectively and potently modulate protein–protein interactions have recently reached clinical trials. Along with high-throughput screening of compound libraries, combining structural and computational approaches has boosted this formerly minor area of research into a currently tremendously active field. This review highlights the very recent developments in the rational design of protein–protein interaction inhibitors.

Graphical abstract: Rational design of protein–protein interaction inhibitors

Article information

Article type
Review Article
Submitted
30 Jul 2014
Accepted
22 Sep 2014
First published
23 Sep 2014

Med. Chem. Commun., 2015,6, 51-60

Author version available

Rational design of protein–protein interaction inhibitors

D. Rognan, Med. Chem. Commun., 2015, 6, 51 DOI: 10.1039/C4MD00328D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements